Society of Hematologic Oncology Insider news
Society of Hematologic Oncology Insider news
Podcast Description
SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology
Podcast Insights
Content Themes
The podcast mainly covers advancements in hematologic oncology, including FDA approvals, treatment strategies, and emerging therapies. For example, episodes have explored the journey of belantamab mafodotin for multiple myeloma, challenges in treating TP53-mutated acute myeloid leukemia, and target treatment goals in myeloproliferative neoplasms. It emphasizes practical insights from clinical trials and their impact on patient care.
SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology
In this episode of the SOHO Insider podcast, host Marin Xavier, MD, hematologist and oncologist at Scripps Clinic in San Diego, and Krish Patel, MD, executive director of Hematologic Cancer Research at Sarah Cannon Research Institute, discuss frontline and relapsed management strategies in mantle cell lymphoma.
“In mantle cell lymphoma, disease progression is pretty rapid when patients relapse after a BTK inhibitor, so if I deliver pirtobrutinib, I’m already thinking about what the next step is,” Dr. Patel said.
This episode also covers frontline BTK adoption and managing high-risk or TP53-aberrated disease in younger patients. Plus, an in-depth look into subsequent treatment pathways, including CAR T-cell therapy, bispecific antibody combinations, and options for difficult-to-treat CD20-negative relapses.

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.